Entry and Antibody-Mediated Immune Targeting of Zoonotic Arenaviruses

MRC · United Kingdom government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

May 30, 2029
Response Due
Active
Status

Opportunity Overview

Context and challenges:
Emerging zoonotic viruses can cross the species barrier from animals to humans and constitute a persistent and growing threat to global health. Among these, rodent-borne New World arenaviruses (NWAVs), which are endemic to South America, have been designated by the World Health Organization as ‘Priority Pathogens’ due to their ability to cause severe viral haemorrhagic fever (HF) with human case fatality rates reaching up to 25%. Although a live-attenuated vaccine for one NWAV, Junín virus (JUNV), has been made available to at-risk communities in Argentina (Candid-1), there are no internationally approved therapeutics for preventing or treating NWAV HF.
The NWAV envelope-displayed glycoprotein complex (GP) is presented on the virus surface and facilitates entry of the virion into host-cells. The ability of the GP to interact with the human host-cell surface receptor, transferrin receptor 1 (hTfR1) during host-cell entry is a primary determinant of zoonosis. Despite the importance of this host-cell recognition event, the molecular determinants underlying GP recognition of both native and human TfR1 for genetically diverse HF-causing NW GP1s remain undefined. Further, while the NWAV GP is the target for neutralising antibodies, information about the epitopes that can be targeted to achieve virus neutralisation and protection following vaccination and infection remains limited. Such information is essential for guiding efforts to rationally design immunogens that protect (and cross-protect) against NWAV infection and would provide a fundamental template for evaluating and improving vaccine designs.
Aims:
Our Project has two primary Aims.
Aim-1. We will engineer a recombinant NWAV GP ectodomain trimer exhibiting native-like functional and immunological properties. We will further combine high-resolution structural methods with biophysical and cellular assays to dissect the molecular specificity underlying TfR1-mediated entry of NW...

This is one of 1,831 active United Kingdom Research Development opportunities most of your competitors will never see.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start Free

Solicitation Details

Issuing agencyMRC
CountryUnited Kingdom
CategoryResearch Development
PublishedMay 30, 2026
Procurement stageActive solicitation
Response dueMay 30, 2029
StatusOpen — accepting responses
Official sourceView original notice
Last verifiedAugust 12, 2026

Source: UK Research and Innovation (UKRI) — Open Government Licence v3.0.

Related Opportunities in United Kingdom

Rotation year
Title of project: Evaluation of the quantitative accuracy and radiation dosimetry of an advanced pre-clinical multipinhole SPECT/CT theranostic imag
Discerning MCT1s role in chromatin remodelling and metabolomics changes in cancer progression
Leveraging real world data to characterise the long term impact of COVID-19
Bacterial antibiotic resistance: structure, mechanism and inhibition of ABC transporters responsible for drug efflux and cell wall biogenesis.
Characterising the role of TEX12 in centrosome and cilia development
Allogeneic Chondroprogenitor Therapy (Phase II) (ACT2)
Iron and immunity

See every United Kingdom Research Development opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free United Kingdom Research Development intelligence report in your inbox

A personalized report on United Kingdom Research Development opportunities, emailed in 5-10 minutes. One per month, no account needed.